Weight Loss Jabs Could Leave Users 'Worse Off Than Before' After Stopping Treatment
New research from the University of Cambridge has issued a stark warning about weight loss injections like Mounjaro and Wegovy, suggesting users could end up in a worse health position than before they started treatment if they regain weight as fat after stopping the drugs.
Significant Weight Regain Documented in Clinical Trials
The comprehensive study, published in the medical journal eClinicalMedicine, analyzed data from six clinical trials involving more than 3,200 participants who had been taking GLP-1 receptor agonist medications. These drugs, originally developed for type 2 diabetes management, work by mimicking the GLP-1 hormone to regulate blood sugar levels and suppress appetite, creating a feeling of fullness that reduces food intake.
Researchers discovered that within 52 weeks of discontinuing treatment, participants regained an average of 60 percent of the weight they had lost while taking the medications. Although this regain eventually plateaued at around 75 percent of the original weight loss by 60 weeks post-treatment, meaning patients maintained approximately 25 percent of their weight loss long-term, the composition of that regained weight raises serious health concerns.
The Critical Issue of Body Composition Changes
Study author Brajan Budini explained the mechanism behind both the initial success and subsequent challenges: "Drugs such as Ozempic and Wegovy act like brakes on our appetite, making us feel full sooner, which means we eat less and therefore lose weight. When people stop taking them, they are essentially taking their foot off the brake, and this can lead to rapid weight regain."
The researchers highlighted a particularly troubling finding: approximately half of the weight lost during treatment typically consists of muscle mass rather than fat. If the weight regained after stopping treatment is disproportionately composed of fat rather than muscle, patients could end up with a worse fat-to-lean mass ratio than they had before starting treatment.
"If the regained weight is disproportionately fat, individuals may ultimately be worse off than before in their fat-to-lean mass ratio, which may have adverse consequences for their health," Budini cautioned. This metabolic shift could potentially increase long-term health risks despite the temporary weight loss achieved during treatment.
Inconsistent Guidelines and Recommendations for Patients
The Cambridge researchers identified significant inconsistencies in current prescribing guidelines for GLP-1 receptor agonists, noting they are "largely inadequate in addressing the risk of weight regain following treatment cessation." For instance, while the National Institute for Health and Care Excellence recommends that patients should take Wegovy for weight loss for a maximum of two years, there is no such time limit specified for Mounjaro prescriptions.
Co-author Steven Luo emphasized the importance of comprehensive patient support: "When stopping weight loss drugs, doctors and patients should be aware of the potential for weight regain and consider ways to mitigate this risk. It's important that people are given advice on improving their diet and exercise, rather than relying solely on the drugs, as this may help them maintain good habits when they stop taking them."
Calls for Further Research and Improved Treatment Protocols
The research team has called for future clinical trials to specifically investigate the effect of GLP-1 receptor agonists on body composition during both active treatment and the post-treatment period. Understanding whether regained weight consists primarily of fat or includes appropriate muscle restoration is crucial for assessing the long-term health implications of these increasingly popular medications.
These findings come as weight loss jabs have gained significant attention and approval for NHS use in tackling obesity, despite their original development as diabetes treatments. The research underscores the complex nature of pharmaceutical weight management and the importance of considering long-term outcomes beyond initial weight reduction numbers.
